AuroLase® Therapy—a nanoparticle-enabled focal therapy—has the potential to safely and effectively treat localized prostate cancer (PCa), preserving baseline functionality. This article presents a detailed case of localized PCa treated with AuroLase, providing insight on expectations from the diagnosis of PCa to one year post-treatment. AuroLase Therapy is a two-day treatment consisting of a systemic infusion of gold nanoshells (~150-nm hydrodynamic diameter) on Day 1, and sub-ablative laser treatment on Day 2. Multiparametric MRI (mpMRI) was used for tumor visualization, treatment planning, and therapy response assessment. The PCa was targeted with a MR/Ultrasound-fusion (MR/US) transperineal approach. Successful treatment was confirmed at 6 and 12 months post-treatment by the absence of disease in MR/US targeted biopsies. On the mpMRI, confined void space was evident, an indication of necrotic tissues encompassing the treated lesion, which was completely resolved at 12 months, forming a band-like scar with no evidence of recurrent tumor. The patient’s urinary and sexual functions were unchanged. During the one-year follow-up, changes on the DCE sequence and in the Ktrans and ADC values assist in qualitatively and quantitatively evaluating tissue changes. The results highlight the potential of gold-nanoparticle-enabled sub-ablative laser treatment to target and control localized PCa, maintain quality of life, and preserve baseline functionality.
Focal therapy aims to provide a durable oncological treatment option for men with prostate cancer (PCa), while preserving their quality of life. Most focal therapy modalities rely on the direct tissue effect, resulting in a possible nontargeted approach to ablation. Here, we report the results of the first human feasibility trial utilizing nanoparticle-directed focal photothermal ablation for PCa. A prospective open-label, single-arm multicenter study of men with localized PCa in the Gleason Grade Group (GGG) 1 to 3 was conducted. Men received a single infusion of gold nanoparticles (AuroShells), followed by MR/US fusion-guided laser excitation of the target tissue to induce photothermal ablation. MRI was used to assess the effectiveness of prostate tissue ablation at 48 to 96 hours, 3-months, and 12-months post-treatment. At 3 months, a targeted fusion biopsy of the lesion(s) was conducted. At 12 months a targeted fusion biopsy and standard templated biopsy were performed. Treatment success was determined based on a negative MR/US fusion biopsy outcome within the treated area. Forty-six men were enrolled in the study, and 44 men with 45 lesions completed nanoparticles infusion and laser treatment. The mean PSA level at baseline was 9.5 ng/mL, which decreased 5.9 ng/mL at 3-months and 4.7 ng/mL at 12-months (P < .0001). The oncologic success rates at 3- and 12-months resulted in 29 (66%) and 32 (73%) of 44 patients, respectively, being successfully treated confirmed with negative MR/US fusion biopsies within the ablation zone. Among GGG, maximum-lesion-diameter (MLD) on MRI, prostate volume, and PI-RADS scoring, the MLD was significantly associated with the odds of treatment failure at 12-months (P = .046). Nanoparticle-directed focal laser ablation of neoplastic prostate tissue resulted in 73% patients with successful treatment at 12-months post-treatment, confirmed by negative MR/US fusion biopsy of the treated lesion and a systematic biopsy.